Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma

ABSTRACT Hepatitis B virus (HBV) exists as quasispecies (QS). However, the evolutionary characteristics of haplotypes of HBV X gene in the hepatocellular carcinoma (HCC) microenvironment remain unclear. Mutations across X gene are essential for the tumorigenicity of HBV X protein (HBx). However, the functional phenotypes of many mutant HBx remain unknown. This study aims to compare the characteristics of X gene evolution between tumour and non-tumour tissues in HCC patients and investigate the tumorigenic phenotype of HBx harbouring mutation T81P/S101P/L123S. This study included 24 HCC patients. Molecular cloning of X gene was performed to analyse characteristics of haplotypes in liver tissues. HCC cell lines stably expressing wild-type or mutant HBx and subcutaneous tumour xenograft mouse model were used to assess HBx-T81P/S101P/L123S tumorigenicity. The mean heterogeneity of HBV QS across X gene in tumour tissues was lower than that in non-tumour tissues. A location bias was observed in X gene clones with genotype C or D in tumour tissues compared to those with genotype B. Mutations in genotype-C or – D clones were mainly clustered in the dimerization region and aa110-aa140 within the transactivation region. A novel mutation combination at residues 81, 101 and 123 was identified in tumour tissues. Further, HBx-T81P/S101P/L123S promotes cell proliferation and increases genomic instability, which was mediated by MYC. This study elucidates the compartmentalized evolution patterns of HBV X gene between intra tumour and non-tumour tissues in HCC patients and provides a new mechanism underlying HBV-driven hepatocarcinogenesis, suggesting a potential viral marker for monitoring HCC.

[1]  Fang Wang,et al.  c-Myc-activated USP2-AS1 suppresses senescence and promotes tumor progression via stabilization of E2F1 mRNA , 2021, Cell Death & Disease.

[2]  S. Ficarro,et al.  BRCA1 binds TERRA RNA and suppresses R-Loop-based telomeric DNA damage , 2021, Nature Communications.

[3]  Hui Zhang Regulation of DNA Replication Licensing and Re-Replication by Cdt1 , 2021, International journal of molecular sciences.

[4]  G. Cao,et al.  Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma. , 2020, Carcinogenesis.

[5]  P. Marcellin,et al.  Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase , 2020, Hepatology.

[6]  C. Winkler,et al.  The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways , 2020, Viruses.

[7]  Q. Ou,et al.  Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients , 2020, Emerging microbes & infections.

[8]  A. Danckaert,et al.  USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis , 2019, Gut.

[9]  Y. Fujiwara,et al.  HBx and c-MYC Cooperate to Induce URI1 Expression in HBV-Related Hepatocellular Carcinoma , 2019, International journal of molecular sciences.

[10]  L. Sticchi,et al.  A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals , 2019, International journal of environmental research and public health.

[11]  F. Ceccherini‐Silberstein,et al.  The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Mingxiong Guo,et al.  Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR‐192‐3p‐XIAP Through NF kappa B Signaling , 2019, Hepatology.

[13]  Ding‐Shinn Chen,et al.  Hepatitis B virus infection , 2018, Nature Reviews Disease Primers.

[14]  E. Hildt,et al.  Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection , 2018, Alimentary pharmacology & therapeutics.

[15]  Lei Zheng,et al.  The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma , 2018, Molecular Cancer.

[16]  Fu-Sheng Wang,et al.  Current advances in the elimination of hepatitis B in China by 2030 , 2017, Frontiers of Medicine.

[17]  K. Aird,et al.  Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer , 2017, Front. Oncol..

[18]  F. Sanai,et al.  Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients , 2017, Oncotarget.

[19]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[20]  J. Kao,et al.  Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. , 2017, Best practice & research. Clinical gastroenterology.

[21]  Ming-jie Wang,et al.  Characteristics of CpG Islands and their quasispecies of full-length hepatitis B virus genomes from patients at different phases of infection , 2016, SpringerPlus.

[22]  M. Yuen,et al.  Hepatitis B virus full‐length genomic mutations and quasispecies in hepatocellular carcinoma , 2016, Journal of gastroenterology and hepatology.

[23]  Bum-Joon Kim,et al.  X region mutations of hepatitis B virus related to clinical severity. , 2016, World journal of gastroenterology.

[24]  J. Jia,et al.  Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia , 2016, Hepatology International.

[25]  Yulan Wang,et al.  HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis. , 2016, Molecular and clinical oncology.

[26]  S. Lee,et al.  Hepatitis B virus X protein enhances Myc stability by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis , 2016, Oncogene.

[27]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[28]  P. Revill,et al.  Overview of hepatitis B viral replication and genetic variability. , 2016, Journal of hepatology.

[29]  Davey M. Smith,et al.  A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. , 2016, Cancer letters.

[30]  F. Liu,et al.  Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection , 2015, Journal of Clinical Microbiology.

[31]  S. Mitani,et al.  Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans , 2012, Proceedings of the National Academy of Sciences.

[32]  C. Hannoun,et al.  Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[33]  C. Lee,et al.  Hepatitis B virus X gene and hepatocarcinogenesis , 2011, Journal of Gastroenterology.

[34]  Yin Jiang,et al.  Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy , 2011, Gut.

[35]  De-min Yu,et al.  Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. , 2009, Journal of hepatology.

[36]  M. Sugiyama,et al.  Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. , 2009, Gastroenterology.

[37]  M. Zheng,et al.  Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint. , 2008, European journal of cancer.

[38]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.

[39]  E. Domingo,et al.  Quasispecies and its impact on viral hepatitis , 2007, Virus Research.

[40]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[41]  C. Bréchot,et al.  Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. , 2001, Cancer research.

[42]  J. Diao,et al.  X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. , 2001, Cytokine & growth factor reviews.

[43]  C. Harris,et al.  Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Teo,et al.  Hepatitis B virus genomic heterogeneity: variation between quasispecies may confound molecular epidemiological analyses of transmission incidents , 1997, Journal of viral hepatitis.

[45]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .